Drug Profile
Research programme: c-Maf gene therapy - Boston Life Sciences/Pfizer
Alternative Names: C-Maf gene therapy; NIP-45Latest Information Update: 09 Aug 2007
Price :
$50
*
At a glance
- Originator Harvard University
- Developer Alseres Pharmaceuticals; Pfizer
- Class Gene therapies; Small molecules
- Mechanism of Action Gene transference; Th1 cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Autoimmune disorders; Hypersensitivity
Most Recent Events
- 09 Aug 2007 Discontinued - Preclinical for Allergy in USA (unspecified route)
- 09 Aug 2007 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 09 Aug 2007 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)